News & Updates

Treatment with ofatumumab in the long term (approximately 3.5 years) among patients with relapsing multiple sclerosis (MS) is well-tolerated, with no new safety risks found, according to the results of ALITHIOS, presented at the 2022 Annual Meeting of the American Academy of Neurology.

The use of a combined biofeedback-virtual reality (VR) device as an add-on to standard medical care leads to a significant reduction in the need for acute medication in patients with chronic migraine, according to a study reported at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).

A recent systematic review has found studies that report cognitive decline among older patients with chronic pain and headache, but some papers have not seen such association.

An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.

Almost 30 percent of patients who experience a cryptogenic stroke or transient ischaemic attack (TIA) go on to develop atrial fibrillation (AF), most of them asymptomatic, according to results of the NOR-FIB* study presented at EHRA 2022.

Adult men with prostate cancer who have increasing exposure to androgen deprivation therapy (ADT) are at greater risk of dementia, according to a US study.